[Funding news] TX-based CrossBridge Bio Secures $10Million in Funding

CrossBridge Bio, a biotechnology company focused on developing advanced cancer treatments using dual-payload antibody-drug conjugates (ADCs), has secured $10 million in funding.

The funding round was led by TMC Venture Fund and CE-Ventures, with additional support from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several early investors.

The company plans to use the funds to advance its lead program, CBB-120, a potential dual-payload ADC designed to treat solid tumors, and to expand its pipeline of new ADC treatments. The money will also help improve the safety and effectiveness of its technology, including its proprietary linker, which plays a key role in making ADCs more effective for cancer therapy.

Read also – [Funding news] NC-based mPATH Secures $3Million in Funding

CEO Michael Torres leads CrossBridge Bio, which aims to improve cancer treatment by using dual-payload ADCs to target and treat hard-to-treat cancers. The company is focused on improving the precision and effectiveness of these therapies to overcome issues like tumor resistance.

As part of this funding, William McKeon, President and CEO of the Texas Medical Center (TMC), and Damir Illich, Ph.D., Manager of Life Sciences at CE-Ventures, will join CrossBridge Bio’s board to offer their expertise and help guide the company’s growth.

About CrossBridge Bio, Inc.

CrossBridge Bio is pioneering next-generation cancer treatments using stable dual-payload antibody-drug conjugates (ADCs). The company’s approach, based on technology developed by Dr. Kyoji Tsuchikama and Dr. Zhiqiang An at UTHealth Houston, includes a proprietary linker that allows for greater stability and the ability to attach multiple drug payloads. This technology is designed to improve treatment outcomes and overcome challenges like tumor resistance.